Optimal Management of Stage IIIA HER2-Positive Breast Cancer After Neoadjuvant Downstaging

Introduction to Guideline Recommendations

• The American Society of Clinical Oncology and European Society for Medical Oncology recommend pertuzumab plus trastuzumab as the standard for Stage II-III HER2-positive disease 1

Adjuvant HER2-Targeted Therapy Strategy

• Complete trastuzumab to 1 year total duration, administered every 3 weeks at 6 mg/kg intravenously, for patients who achieve pathological complete response 6, 1, 2
• Multiple randomized trials demonstrate clinically significant improvements in disease-free survival and overall survival with 1 year of trastuzumab therapy 2
• Switch to trastuzumab emtansine (T-DM1) for 14 cycles instead of continuing trastuzumab if residual invasive disease is present 8, 1, 2, 3
• The KATHERINE trial demonstrated that T-DM1 significantly improves invasive disease-free survival compared to continuing trastuzumab alone in patients with residual disease after neoadjuvant therapy 8, 2

Adjuvant Endocrine Therapy

• Initiate tamoxifen 20 mg orally daily for 5 years, given sequentially after completion of chemotherapy, for premenopausal women with ER-positive and PR-positive disease 5, 6, 2, 3
• Chemotherapy and endocrine therapy must be given sequentially, with endocrine therapy starting after chemotherapy completion 5, 6

Adjuvant Radiation Therapy

• Post-mastectomy radiation therapy to the chest wall and regional lymph nodes is mandatory based on the initial Stage IIIA presentation 2, 3
• Radiation therapy indications must be based on pre-chemotherapy tumor characteristics, not post-neoadjuvant pathology 2, 3

Cardiac Monitoring Requirements

• Evaluate left ventricular ejection fraction (LVEF) prior to continuing trastuzumab and every 3 months during therapy 2

Surveillance Strategy

• Schedule follow-up 7-14 days post-operatively to assess wound healing, drain output, and review final pathology results 3
• Annual mammography of the contralateral breast is recommended 2, 3
• No routine imaging (CT, PET, bone scans) in asymptomatic patients 2, 3

Future Considerations

• Dual HER2 blockade with pertuzumab plus trastuzumab should be standard neoadjuvant therapy for Stage IIIA HER2-positive breast cancer 4, 1